Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present and engage in one-on-one investor meetings at the Jefferies London Healthcare Conference on November 18, 2021, and the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021. The Jefferies event is scheduled for 3 a.m. EST, while the Piper Sandler event will begin at 10 a.m. EST. A webcast will be available for 90 days on Protagonist's website. The company focuses on peptide-based therapies, including treatments for conditions like polycythemia vera and ulcerative colitis.
- None.
- None.
NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler.
Presentation Details:
Event: Jefferies London Healthcare Conference
Date: November 18, 2021
Time: 3 a.m. EST
Event: Piper Sandler 33rd Annual Healthcare Conference
Date: November 22, 2021
Time: 10 a.m. EST
A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.
The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds in development include PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates. The Phase 1 study of PN-235 is completed, and Janssen is expected to initiate a Phase 2 study in psoriasis in early 2022. The Phase 1 study with PN-232 is in progress, with study completion expected by mid-2022. Additional research in IBD is expected to initiate in 2022.
Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences-301421775.html
SOURCE Protagonist Therapeutics, Inc.
FAQ
What are the details of the Jefferies London Healthcare Conference for Protagonist Therapeutics (PTGX)?
When will Protagonist Therapeutics (PTGX) present at the Piper Sandler Healthcare Conference?
How can I access the webcast of Protagonist Therapeutics' (PTGX) investor presentations?
What is the focus of Protagonist Therapeutics' (PTGX) drug development pipeline?
Who is the CEO of Protagonist Therapeutics (PTGX)?
